Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Goldman Reduces Bausch & Lomb to 'In-Line'

Goldman Sachs downgraded Bausch & Lomb (BOL) to in-line from outperform.

Analyst Lawrence Keusch says although he still expects cost cutting to remain on track, shares now trade within 1% of the estimated $40 fair value as determined by a 10-year discounted cash flow analysis. He says shares now are meaningfully ahead of the medical device group's average of 14%.

However, Keusch still expects Bausch & Lomb to meet or exceed the $2.08 2003 earnings per share estimate, based on operational outperformance and the benefits of foreign-exchange rates. Nonetheless, with few near-term catalysts, and with the stock having reached its estimated fair value, Keusch says he now expects the shares to perform in line with his covered universe.

blog comments powered by Disqus